Fennec Pharmaceuticals Inc. reports developments as a commercial-stage specialty pharmaceutical company focused on PEDMARK® (sodium thiosulfate injection), a therapy used to reduce the risk of cisplatin-induced ototoxicity in pediatric patients with localized, non-metastatic solid tumors. The company also markets the product in Europe and the United Kingdom under the PEDMARQSI® name and has disclosed a licensing arrangement for commercialization in additional non-U.S. markets.
Recurring news themes include PEDMARK product sales and financial results, commercialization updates, scientific abstracts, investigator-sponsored and real-world studies in cancer patients receiving cisplatin-based chemotherapy, product exclusivity and patent matters, and equity compensation actions under Nasdaq rules.
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) announced the departure of Adrian Haigh from his role as Chief Operating Officer, effective June 30, 2024. Haigh, who joined the company in August 2023 after serving nine years as an independent director, played a pivotal role in business development and global commercial operations. During his tenure, Fennec secured an exclusive licensing agreement with Norgine to commercialize PEDMARQSI in Europe, Australia, and New Zealand. The company is now seeking a U.S.-based leader to drive its new commercial strategy focused on the community-treated AYA population. CEO Rosty Raykov highlighted the importance of this transition for the company's continued success in oncology product commercialization.
Fennec Pharmaceuticals announced the results of its Annual General Meeting of Shareholders held on June 25, 2024, in New York. The nominees listed in the April 29, 2024, management proxy circular were elected as directors, with high approval ratings. Notably, Dr. Khalid Islam received 96.45% of votes in favor, while Mr. Chris A. Rallis received 92.52%. Shareholders also voted 97.96% in favor of appointing Haskell & White LLP as auditors and 93.87% in favor of the executive compensation plan.
Fennec Pharmaceuticals (NASDAQ: FENC) reported its Q1 2024 financial results, revealing total net revenues of $25.4 million, driven by $18 million in licensing revenue from a new agreement with Norgine. The company executed an exclusive licensing deal with Norgine to commercialize PEDMARQSI™ in Europe, Australia, and New Zealand, receiving $43.2 million upfront, with potential total earnings of up to $230 million. PEDMARK product sales contributed $7.4 million. Cash and equivalents surged to $51.2 million from $13.3 million at the end of 2023. However, selling and marketing expenses rose to $5.2 million, and G&A expenses increased to $5.8 million. Net income reached $12.8 million, a significant turnaround from a $6.1 million loss in Q1 2023. An amended J-code for PEDMARK, effective April 1, 2024, specifies its non-interchangeability with other formulations.
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX) will release its first quarter 2024 financial results on May 14, 2024, before the opening of the U.S. financial markets. A conference call and webcast will be held to discuss the financial and business results on the same day. Details for the call and webcast are provided for registration and access.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.